SCM
ORIC icon

Superstring Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Superstring Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$1.61M – 46
2024
Q4 		$1.61M Buy
+200,000
New +$1.84M 1.4% 20

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Superstring Capital Management's ORIC Position: Q1 2026 in Review

Superstring Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 55% in Q1 2026, selling an estimated $1.59M and leaving 115,234 shares worth $1.46M. The position accounts for 1.04% of the portfolio, ranked #25.

Superstring Capital Management first reported a position in ORIC in Q3 2024 and has held it in 7 quarters since. The position peaked at $12.8M in Q4 2024. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Superstring Capital Management held 115,234 shares of Oric Pharmaceuticals worth $1.46M as of Q1 2026.
  • Superstring Capital Management sold 140,136 Oric Pharmaceuticals shares in Q1 2026, an estimated $1.59M.
  • Oric Pharmaceuticals made up 1.04% of Superstring Capital Management's portfolio in Q1 2026, its #25 holding.
  • Superstring Capital Management first reported a position in Oric Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Superstring Capital Management's Oric Pharmaceuticals position peaked at $12.8M in Q4 2024.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.